We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Out-of-pocket costs and dosing frequency play a big part ...
ARTISTRY-1 trial showed BIC/LEN is effective in maintaining viral suppression in HIV patients previously on complex ART regimens. BIC/LEN offers a single-tablet alternative for patients with drug-drug ...
– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
Results from ARTISTRY trials will be submitted to regulatory agencies for review. Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an ...
Dual screened tablets have always turned out to be more of a crowd favorite than their single screened counterparts and the Kno tablet with dual screens has its fair share of public interest ever ...
– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback